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In the countries we surveyed, the 
highest price for patients paying for 
Xpert testing was in the Philippines, 
while the lowest average price was 
offered in India, via laboratories in 
a network called the Initiative for 
Promoting Aﬀ ordable and Quality TB 
Tests (IPAQT).4 IPAQT, a private sector 
initiative, offers WHO-approved 
diagnostics at concessional prices. 
Laboratories in IPAQT oﬀ er Xpert at 
a ﬁ xed price of INR 2000 ($30·26), 
compared with an average of $52·82 
in the rest of the private sector in 
India. By January, 2016, IPAQT had 
consolidated 110 accredited private 
laboratories that receive concessional 
pricing for Xpert, LPA, and liquid 
cultures. In exchange for access 
to the public sector concessional 
pricing for reagents and equipment, 
member laboratories must agree 
to pass on price reductions to 
patients, by charging no more than 
a transparently agreed ceiling price, 
notifying tuberculosis cases to the 
public sector, and participating in 
quality assurance programmes.5 
Since its launch in 2013, more than 
200 000 tuberculosis tests have been 
done by IPAQT laboratories (H Dabas, 
personal communication).
Xpert MTB/RIF for 
tuberculosis testing: 
access and price in 
highly privatised health 
markets
Xpert MTB/RIF (Cepheid, Sunnyvale, 
CA, USA) is the biggest recent 
advance in tuberculosis diagnosis, 
and since 2010 more than 15 million 
cartridges have been procured through 
concessional pricing ($9·98 per 
cartridge in 2015).1 However, even 
in countries with a high tuberculosis 
burden, the private sector is not 
eligible for concessional pricing for 
Xpert, nor for other WHO-endorsed 
tests such as line probe assays (LPA) 
and liquid cultures. Manufacturers 
set higher prices for reagents and 
instruments for private laboratories 
and institutions than for the public 
sector, and there are additional 
costs (such as import duties), and 
margins imposed by distributors, 
intermediaries, and laboratories. 
Why does private sector pricing 
and access matter? The private sector 
is a major source of health care in 
12 of the 22 countries with the highest 
tuberculosis burden, including India, 
Pakistan, the Philippines, Bangladesh, 
Afghanistan, Kenya, Uganda, Vietnam, 
Indonesia, Myanmar, Nigeria, and 
Cambodia.2,3 In these economies, 
even poor patients with tuberculosis 
seek care from private health-care 
providers, and delayed diagnosis and 
misdiagnosis are important problems.2
Little is known about how 
exclusion from concessional pricing 
programmes affects access to the 
Xpert test, nor the price for patients 
in the private sector. We contacted 
tuberculosis experts in 12 countries 
and asked them to check commercial 
availability of Xpert in their country, 
and collect price data from private 
laboratories that oﬀ er Xpert testing. 
We had at least two respondents 
from each of the 12 countries, and 
they included national tuberculosis 
programme staff, tuberculosis 
researchers and clinicians, and 
agencies such as the Foundation 
for Innovative New Diagnostics 
(FIND) and the Clinton Health Access 
Initiative (CHAI).
As shown in the table, in six of the 
12 countries, there is no commercial 
availability of Xpert in the private 
sector. Patients, however, can access 
the test via the public sector and 
special public-private mix projects. 
In the remaining six countries, the 
average price charged by private 
laboratories was US$68·73 (range 
$30·26–$155·44). While the exact 
cost breakdown is unknown, the ﬁ nal 
price paid by patients included cost of 
reagents and instruments, shipping, 
import duties, distributor margins, 
laboratory profit margins, and, in 
some settings, incentives for doctors 
who order the test. By comparison, the 
public sector in each of these countries 
offers testing with Xpert at no cost 
to patients. The fully loaded cost of 
Xpert for the public sector has been 
estimated to be about $20–30 per test, 
depending on whether machines are 
used at maximum capacity and other 
operational factors (H Sohn, personal 
communication).
Mean price for 
Xpert MTB/RIF
Range Private laboratories 
oﬀ ering Xpert 
MTB/RIF (N)
Laboratories 
contacted for price 
information (N)
Kenya $80·60 $51–$171 5 5
India
IPAQT member laboratories $30·26 Fixed Price 76 ..
Rest of private sector $52·82 $27·84–$86·55 60 13
Pakistan $37·26 $25·96–$58·65 4 4
Philippines $155·44 $128–$183 11 9
Bangladesh $74·75 $45·50–$130 4 4
Afghanistan $50·00 .. 1 1
Uganda No Xpert .. 0 ..
Vietnam No Xpert .. 0 ..
Indonesia No Xpert .. 0 ..
Myanmar No Xpert .. 0 ..
Nigeria No Xpert .. 0 ..
Cambodia No Xpert .. 0 ..
More than 50% of primary health-care visits were to a private health-care provider in the countries shown.4 Prices correct at September, 2015. 
IPAQT=Initiative for Promoting Access to Quality TB Tests.
Table: Price paid by private patients for Xpert MTB/RIF in 12 high burden countries with high rates of private health-care use
Correspondence
e95 www.thelancet.com/lancetgh   Vol 4   February 2016
We are grateful to colleagues in 12 countries for 
sending us information. We thank Harkesh Dabas 
(CHAI, New Delhi, India), Prashant Yadav (University 
of Michigan, Ann Arbor, USA), and Puneet Dewan 
(Bill & Melinda Gates Foundation, New Delhi, India) 
for their helpful input on the analysis. LP and CO 
declare no competing interests. CMD is employed 
by FIND, Geneva; MP declares no competing 
interests, but is a consultant to the Bill & Melinda 
Gates Foundation, on the Scientiﬁ c Advisory 
Committee of FIND, and part of the Governing 
Council of IPAQT in India, coordinated by CHAI, 
New Delhi, India.
Copyright © Puri et al. Open Access article 
distributed under the terms of CC BY.
Lekha Puri, Collins Oghor, 
Claudia M Denkinger, *Madhukar Pai
madhukar.pai@mcgill.ca
McGill International Tuberculosis Center, McGill 
University, Montreal, Canada (LP, CO, MP); FIND, 
Geneva, Switzerland (CMD); and Department of 
Epidemiology and Biostatistics, 1020 Pine Avenue 
West, Montreal QC H3A 1A2, Canada (MP)
 1 WHO. WHO monitoring of Xpert MTB/RIF 
roll-out. http://www.who.int/tb/laboratory/
mtbrifrollout/en/index.html (accessed 
Oct 6, 2015). 
 2 Wells WA, Uplekar M, Pai M. Achieving 
systemic and scalable private sector 
engagement in tuberculosis care and 
prevention in Asia. PLoS Med 2015; 
12: e1001842.
3 Global Health Group at UCSF. Private 
healthcare in developing countries. http://
ps4h.org/globalhealthdata.html (accessed 
Jan 6, 2016).
 4 IPAQT. Initiative for promoting aﬀ ordable & 
quality TB tests. http//:www.ipaqt.org 
(accessed Oct 6, 2015).
 5 Pai M. Promoting aﬀ ordable and quality 
tuberculosis testing in India. J Lab Physicians 
2013; 5: 1–4.
 6 Salje H, Andrews JR, Deo S, et al. The 
importance of implementation strategy in 
scaling up Xpert MTB/RIF for diagnosis of 
tuberculosis in the Indian health-care system: 
a transmission model. PLoS Med 2014; 
11: e1001674.
 7 Pai M, Yadav P, Anupindi R. Tuberculosis 
control needs a complete and patient-centric 
solution. Lancet Glob Health 2014; 2: e189–90.
Our findings suggest that 
commercial sale of Xpert seem to be 
limited, and, with some exceptions, 
patients in the private sector pay a 
lot for this test. These factors could 
result in low levels of access to quality 
tests and blunt the benefits of new 
diagnostic tools.6 However, since 
we were unable to access data for 
the numbers of tests done in public 
facilities versus the private providers, 
our results are only suggestive. 
However, our data do underscore the 
need for a private sector access strategy 
to ensure that quality diagnostics 
reach all patients with suspected 
tuberculosis. The strategy will need to 
draw on various approaches, such as 
the inclusion of the private sector in 
current and future pricing agreements, 
replication of IPAQT-like models in 
other economies, consolidation of 
private laboratories by intermediary 
agencies, public-private mix projects 
to allow privately managed patients 
to be tested in public facilities, use 
of subsidies and vouchers by private 
provider interface agencies, and 
social businesses to cross-subsidise 
tuberculosis tests against more 
proﬁ table tests. Product manufacturers 
will need to realise that most patients 
with tuberculosis in countries with a 
high burden of the disease have limited 
means, and a mass-market (that 
is, a low margin, but high volume) 
rather than premium (high margin, 
but low volume) pricing model may 
be more appropriate for tuberculosis 
tests in these countries. The IPAQT 
experience supports this theory. Lastly, 
access to good diagnostic tests will 
not necessarily improve tuberculosis 
outcomes in the private sector. This will 
require a comprehensive public-private 
model that offers patient centric, 
quality care.2, 7
